MICs of six extended-spectrum cephalosporins (cefotaxime, ceftriaxone, ceftazidime, FK 037, cefpirome, cefepime), three carbapenems (imipenem, meropenem, biapenem), and vancomycin for 49 penicillin-susceptible (S), 77 penicillin intermediate-resistant (I), and 51 penicillin-resistant (R) pneumococci were determined by agar dilution. Compared with ceftazidime (MICs for 90%o of strains tested [MIC90s] of 2.0, 16.0, and 16.0 ,ug/ml for S, I, and R strains, respectively), all other cephalosporins yielded lower MICs (MIC,0s of 0.06 to 0.125, 0.5 to 1.0, and 1.0 to 2.0 ,ug/ml against S, I, and R strains, respectively). All three carbapenems were very active, with MIC%0s, even for R strains, of .1.0 ,ug/ml. All strains were susceptible to vancomycin (MIC90 of 0.5 ,ug/ml).
Streptococcus pneumoniae continues to be a significant cause of morbidity and mortality in humans and is the leading cause of bacterial pneumonia, as well as being an important cause of otitis media and meningitis. The past two decades, and in particular the past 5 years, have witnessed a dramatic increase in the incidence of pneumococcal strains which are resistant to penicillin G (R) and other antimicrobial agents (1) . In the United States, surveys performed before 1990 showed a prevalence of 4 to 5% (1). One report documented an incidence of 17.8% between 1990 and 1991 (24) . It is not clear whether this increased incidence applies to the whole country or only applies to certain areas. In the absence of recent confirmatory multistate surveys, we do not know precisely the magnitude of this problem in the United States. Although nonmeningitic infections caused by R strain pneumococci may be treated under certain circumstances with high doses of penicillin and other 1-lactams, treatment may not always be successful (17) .
By contrast, clinical failure of penicillin in treatment of meningitis caused by strains intermediately resistant to penicillin (I) approaches 80%, and no cases of meningitis caused by strains fully resistant to penicillin have responded to penicillin therapy (25) .
There is an urgent need for antimicrobial agents which can be used for therapy of systemic infections (and especially meningitis) caused by R strain pneumococci. The aim of the current study was to examine the activity of six extendedspectrum cephalosporins (ceftazidime, cefotaxime, ceftriaxone, FK The results of susceptibility testing are presented in Table 1 as the cumulative percentage inhibited at a specific MIC. As can be seen, the susceptibility of all cephalosporins and carbapenems increased in line with the MIC of penicillin. Ceftazidime was the least active of the cephalosporins, with MICs for 90% of the S, I, and R strains tested of 2.0, 16.0, and 16.0 ,ug/ml, respectively. By contrast, all other cephalosporins showed greater activity, with MICs for 90% of the S, I, and R strains tested of 0.06 to 0.125, 0.5 to 1.0, and 1.0 to 2.0 ,ug/ml, respectively. MICs of FK 037, cefpirome, cefepime, cefotaxime, and ceftriaxone were very similar for all classes of pneumococcal strains. All three carbapenems were very active, with all strains susceptible at MICs of '1.0 p,g/ml. All strains were susceptible to vancomycin at MICs of 50.5 jig/ml.
High MICs of ceftazidime, in contrast to the lower MICs of both cefotaxime and ceftriaxone for I and R pneumococcal strains, have been described before (16, 25) . FK 037, cefpirome, and cefepime are all new extended-spectrum cephalosporins with broad-spectrum antimicrobial activity against gram-positive and gram-negative organisms equal or superior to that of existing broad-spectrum cephalosporins (2, 3, 6, 10, 11, (14) (15) (16) 21) . Geslin and coworkers (6) and Lifiares and coworkers (16) have documented good in vitro activity of cefpirome against S, I, and R pneumococci (MICs for 90% of the strains tested of s0.03, 0.5, and 1.0 ,ug/ml, respectively).
Our results confirm the latter findings and extend them to FK 037 and cefepime. Low imipenem MICs for all groups of pneumococci have been described before (16, 25) . The current study documents comparably low MICs for these organisms of meropenem (13) and biapenem, a new broad-spectrum carbapenem which is also stable in response to human renal dehydropeptidase (20, 26) . Although MICs of carbapenems increased with the penicillin MIC, all strains were susceptible at MICs of 51.0 ug/ml. The uniform susceptibility of all pneumococcal strains to vancomycin has been amply documented (16, 25) .
Although 
